

December 23, 2025

<p>To</p> <p>The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</p> <p>Code: 540222</p>	<p>To</p> <p>The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051</p> <p>Code: LAURUSLABS</p>
--	--

Sub: Update on proposed equity investment in KRKA Pharma Private Limited under Regulation 30(7) of SEBI (LODR) Regulations, 2015

Ref: Our intimation letter dated 25th July, 2025

Dear Sir / madam,

In continuation to our letter dated July 25, 2025 with regard to proposed acquisition of equity shares in KRKA Pharma Private Limited (“KRKA”) (a joint venture of the Company) and as per Regulation 30(7) of SEBI (LODR) Regulations, 2015, we would like to inform you that the Company has invested INR 490,000,000/- (Indian Rupees Four Hundred and Ninety Million only) and acquired 49,000,000 (Forty Nine Million) equity shares of KRKA at face value of INR 10/- each aggregating to an amount of INR 490,000,000/- (Indian Rupees Four Hundred and Ninety Million only) by way of rights issue.

Please take the above information on record.

Yours faithfully,

For Laurus Labs Limited

G. Venkateswar Reddy

Company Secretary & Compliance Officer

Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320